These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 15341878)

  • 1. Development of and clinical experience with capecitabine (Xeloda) in the treatment of solid tumours.
    Sternberg CN; Reichardt P; Holland M
    Eur J Oncol Nurs; 2004; 8 Suppl 1():S4-15. PubMed ID: 15341878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda).
    Marsé H; Van Cutsem E; Grothey A; Valverde S
    Eur J Oncol Nurs; 2004; 8 Suppl 1():S16-30. PubMed ID: 15341879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications of capecitabine (Xeloda) for cancer nursing practice.
    Gerbrecht BM; Kangas T
    Eur J Oncol Nurs; 2004; 8 Suppl 1():S63-71. PubMed ID: 15341883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer.
    Wagstaff AJ; Ibbotson T; Goa KL
    Drugs; 2003; 63(2):217-36. PubMed ID: 12515569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Capecitabine].
    Yamaguchi K; Shimamura T; Tada M
    Gan To Kagaku Ryoho; 2006 Jul; 33(7):891-5. PubMed ID: 16835474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The rational development of capecitabine from the laboratory to the clinic.
    Pentheroudakis G; Twelves C
    Anticancer Res; 2002; 22(6B):3589-96. PubMed ID: 12552961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness.
    Twelves CJ
    Clin Colorectal Cancer; 2006 Nov; 6(4):278-87. PubMed ID: 17241512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral capecitabine: bridging the Atlantic divide in colon cancer treatment.
    Van Cutsem E; Verslype C; Tejpar S
    Semin Oncol; 2005 Feb; 32(1):43-51. PubMed ID: 15726505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capecitabine: a new adjuvant option for colorectal cancer.
    Berg DT
    Clin J Oncol Nurs; 2006 Aug; 10(4):479-86. PubMed ID: 16927901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers.
    Ajani J
    Cancer; 2006 Jul; 107(2):221-31. PubMed ID: 16770784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
    Twelves C; Boyer M; Findlay M; Cassidy J; Weitzel C; Barker C; Osterwalder B; Jamieson C; Hieke K;
    Eur J Cancer; 2001 Mar; 37(5):597-604. PubMed ID: 11290435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How the new oral antineoplastics affect nursing practice: capecitabine serves to illustrate.
    Szetela AB; Gibson DE
    Am J Nurs; 2007 Dec; 107(12):40-8; quiz 48-9. PubMed ID: 18049060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral fluoropyrimidines among the new drugs for patients with metastatic breast cancer.
    Leonard RC
    Br J Cancer; 2001 Jun; 84(11):1437-42. PubMed ID: 11384089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer.
    Leonard R; Hennessy BT; Blum JL; O'Shaughnessy J
    Clin Breast Cancer; 2011 Dec; 11(6):349-56. PubMed ID: 21856245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The vital role of education and information in patients receiving capecitabine (Xeloda).
    Chau I; Legge S; Fumoleau P
    Eur J Oncol Nurs; 2004; 8 Suppl 1():S41-53. PubMed ID: 15341881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda).
    Lassere Y; Hoff P
    Eur J Oncol Nurs; 2004; 8 Suppl 1():S31-40. PubMed ID: 15341880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capecitabine in the treatment of colorectal cancer.
    O'Neill VJ; Cassidy J
    Future Oncol; 2005 Apr; 1(2):183-90. PubMed ID: 16555988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capecitabine in breast cancer: current status.
    Smorenburg CH; Bontenbal M; Verweij J
    Clin Breast Cancer; 2001 Jan; 1(4):288-93; discussion 294. PubMed ID: 11899351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
    Cunningham D; Coleman R
    Cancer Treat Rev; 2001 Aug; 27(4):211-20. PubMed ID: 11545541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.